No Data
Hitgen Inc. (688222.SH) shareholder Shenzhen Jun Tian has completed the Shareholding of 2.1754 million shares.
Hitgen Inc. (688222.SH) announced that its Shareholder Shenzhen Jun Tian Investment Enterprise (Limited Partnership) (referred to as '...')
The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?
Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.
Hitgen Inc. (688222.SH): Plans to acquire approximately 65% equity in Nanjing Haina Pharmaceutical Technology.
On March 31, at Gelonghui, Hitgen Inc. (688222.SH) announced that the company is planning to acquire approximately 65% of the shares of Nanjing Haina Pharmaceutical Technology Co., Ltd. (referred to as the "symbol company") through a cash transfer of shares. After the completion of this Trade, Hitgen Inc. will become the controlling shareholder of the symbol company. This Trade does not constitute a related party transaction. Preliminary calculations indicate that this Trade is expected to constitute a major asset reorganization as defined by the "Administrative Measures for Major Asset Restructuring of Listed Companies."
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
HitGen (SHSE:688222) Seems To Use Debt Rather Sparingly
Time To Worry? Analysts Are Downgrading Their HitGen Inc. (SHSE:688222) Outlook